S&P Futures
6,011.00 +24.00 (+0.40%) Dow Futures
44,629.00 +234.00 (+0.53%) Nasdaq Futures
20,959.50 +109.75 (+0.53%) Russell 2000 Futures
2,435.70 +22.10 (+0.92%) Crude Oil
70.58 -0.66 (-0.93%) Gold
2,670.80 -41.40 (-1.53%)
Molecular Partners AG (MOLN)
| Previous Close | 5.44 |
| Open | 5.29 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.29 - 5.29 |
| 52 Week Range | 3.32 - 12.70 |
| Volume | |
| Avg. Volume | 18,201 |
| Market Cap | 201.418M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.13 |
| Earnings Date | Nov 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 |
GlobeNewswireMolecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs k
- GlobeNewswire
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of c
